| Identification | Back Directory | [Name]
4-({4-[(2,6-dimethylpyridin-3-yl)oxy]pyridin-2-yl}amino)benzenesulfonamide | [CAS]
1117684-36-2 | [Synonyms]
AZ12799734
4-({4-[(2,6-dimethylpyridin-3-yl)oxy]pyridin-2-yl}amino)benzenesulfonamide
Benzenesulfonamide, 4-[[4-[(2,6-dimethyl-3-pyridinyl)oxy]-2-pyridinyl]amino]- | [Molecular Formula]
C18H18N4O3S | [MDL Number]
MFCD26397939 | [MOL File]
1117684-36-2.mol | [Molecular Weight]
370.43 |
| Hazard Information | Back Directory | [Biochem/physiol Actions]
AZ12799734 is an orally active TGF-β type I receptors active site inhibitor (ALK1/2/3/4/5/6 Kd = 7.1/6.2/40/1/0.74/0.017 μM) that inhibits ALK5-dependent Smad2 nuclear translocation upon TGF-β1 stimulation (IC50 = 17 nM; MDA-MB-468), as well as ALK1/2/3/6-mediated Smad1 and ALK4/5/7-mediated Smad2 phosphorylation (10 μM; NIH3T3 expressing respective constitutively active receptors). AZ12799734 oral administration in rats results in heart valve lesions (200 mg/kg/day for 5 days) and physeal dysplasia (400 mg/kg/day for 6 days), consistent with a critical role of ALK5 in maintaining the integrity of heart valve and physis. | [storage]
Store at -20°C |
|
|